SCHEMBL1962867

SCHEMBL1962867

COc1cccc(OC)c1-n1c(C)nc2ccccc2c1=O

nearest known ligand 0.64

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.64
L3MBTL1 Q9Y468 3/20 0.59
LMNA P02545 2/20 0.57
ALDH1A1 P00352 2/20 0.57
HTT P42858 1/20 0.56
HSD17B10 Q99714 1/20 0.56
POLB P06746 2/20 0.54
TSHR P16473 1/20 0.54
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
GLA P06280 1/20 0.53
MAPK1 P28482 1/20 0.52
ALOX12 P18054 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29154636 0.78 SMN1; SMN2 (1.00) SMN1; SMN2LMNAALDH1A1HSD17B10POLB
SCHEMBL30726095 0.78 SMN1; SMN2 (1.00) SMN1; SMN2LMNAALDH1A1HSD17B10POLB
SCHEMBL29154649 0.77 ALDH1A1 (0.76) SMN1; SMN2LMNAALDH1A1HTTPOLB
SCHEMBL30122631 0.77 MAPK1 (0.75) SMN1; SMN2L3MBTL1LMNAALDH1A1HTT
SCHEMBL1682746 0.77 MAPK1 (0.75) SMN1; SMN2L3MBTL1LMNAALDH1A1HTT
SCHEMBL14022261 0.76 LMNA (0.61) SMN1; SMN2LMNAHTTPOLBMEN1
SCHEMBL1964823 0.76 LMNA (0.63) SMN1; SMN2LMNAHTTPOLBMEN1
SCHEMBL1964825 0.76 LMNA (0.63) SMN1; SMN2LMNAHTTPOLBMEN1
SCHEMBL14303440 0.74 L3MBTL1 (0.64) L3MBTL1LMNAALDH1A1TSHRMEN1
SCHEMBL1129588 0.73 L3MBTL1 (0.68) SMN1; SMN2L3MBTL1LMNAALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170224687-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES INC (US) 2017-08-10 US disclosed
US-20170224687-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES INC (US) 2017-08-10 US disclosed
US-20170224687-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES INC (US) 2017-08-10 US disclosed
US-9486455-B2 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES, INC. (US) 2016-11-08 US disclosed
US-9486455-B2 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES, INC. (US) 2016-11-08 US disclosed
US-9486455-B2 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES, INC. (US) 2016-11-08 US disclosed
US-20140155417-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES, INC. (US) 2014-06-05 US disclosed
US-20140155417-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES, INC. (US) 2014-06-05 US disclosed
US-20140155417-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES, INC. (US) 2014-06-05 US disclosed
US-8552009-B2 Substituted pyrimido 4.5-d pyrimidin-4-one compounds for modulating TRPV3 function HYDRA BIOSCIENCES, INC. 2013-10-08 US disclosed
US-20090018147-A1 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES INC. (US) 2009-01-15 US disclosed
US-20090018147-A1 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES INC. (US) 2009-01-15 US disclosed
US-20090018147-A1 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES INC. (US) 2009-01-15 US disclosed
WO-2008140750-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES INC. (US) 2008-11-20 WO disclosed
WO-2008140750-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES INC. (US) 2008-11-20 WO disclosed
EP-1954283-A2 COMPOUNDS FOR MODULATING TRPV3 FUNCTION Hydra Biosciences, Inc. (US) 2008-08-13 EP disclosed
US-20070179164-A1 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES, INC. (US) 2007-08-02 US disclosed
US-20070179164-A1 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES, INC. (US) 2007-08-02 US disclosed
US-20070179164-A1 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES, INC. (US) 2007-08-02 US disclosed
WO-2007056124-A2 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140155417-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION TRPV3, TRPV1, TRPV4 SMN1; SMN2 2219/4885L3MBTL1 4457/4885LMNA 3054/4885
US-20090018147-A1 Compounds for modulating TRPV3 function TRPV3, TRPV1, TRPV4 SMN1; SMN2 2219/4885L3MBTL1 4457/4885LMNA 3054/4885
US-20070179164-A1 Compounds for modulating TRPV3 function TRPV3, TRPV1, TRPV4 SMN1; SMN2 2219/4885L3MBTL1 4457/4885LMNA 3054/4885
US-20170224687-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION TRPV3, TRPV1, TRPV4 SMN1; SMN2 2219/4885L3MBTL1 4457/4885LMNA 3054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.